Skip to main content

Aardvark Therapeutics, Inc.

corporate_fare Company Profile

Aardvark Therapeutics, Inc.

AARD·NASDAQ·Life Sciences·CIK 0001774857

Aardvark Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops new small-molecule treatments to activate natural homeostatic pathways for metabolic diseases. The company focuses on biological pathways linked to hunger relief, aiming for significant patient outcomes. Aardvark Therapeutics develops selective compounds that target Bitter Taste Receptors (TAS2Rs) for conditions related to hunger. Its initial compounds target TAS2Rs found in the gut lumen, which typically respond to food chemicals and are part of the gut-brain axis. Research indicates that activating these receptors can trigger the release of natural signaling molecules such as cholecystokinin (CCK), peptide YY (PYY), and glucagon-like peptide-1 (GLP-1). TAS2Rs are a family of 26 nutrient-sensing G protein-coupled receptors (GPCRs) found in vertebrates, present in the mouth for bitter taste and highly expressed in other tissues where they regulate metabolic and inflammatory pathways. CCK is a pharmaceutical target known to suppress hunger. The company's wholly-owned lead product candidate, ARD-101, is an oral, largely gut-restricted small-molecule agonist of specific TAS2Rs in the gut lumen. ARD-101 induces the body's natural release of CCK through TAS2R agonism, differing from prior approaches that directly agonized CCK receptors and faced safety concerns due to systemic exposure and adverse effects like pancreatitis. Aardvark Therapeutics is not aware of any other approved or clinical-stage candidates targeting certain TAS2Rs besides its own.

Aardvark Therapeutics, Inc. (NASDAQ:AARD) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 26 items for AARD at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • Aardvark Therapeutics Pauses Lead Phase 3 Drug Trial Over Cardiac Safety Signals
  • Aardvark Therapeutics Pauses Key Phase 3 Trial for ARD-101 Due to Cardiac Safety Observations
  • Cardiac Safety Concerns Halt Aardvark's Phase 3 Prader-Willi Trial
  • Aardvark Therapeutics Establishes Dermatology Subsidiary, Appoints CEO, and Expands Executive Team
  • Aardvark Therapeutics Expands Phase 3 Trial Eligibility for Lead PWS Drug ARD-101 to Younger Children

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$57.59M
Diluted EPS
-$2.93
Op. Cash Flow
-$54.17M
Free Cash Flow
-$54.27M
Operating Income
-$62.73M
Cash & Equivalents
$47.05M
Debt / Equity
0.00×
Shares Outstanding
21.82M sh
Source: 10-K · filed 2026-03-23 · accession 0001193125-26-119770
$0.9226
52-week range · as of 2026-11-13 $0.9226 – $16.6
Market cap
$20.2M
Volume
241.1K (0.2× avg)
3-mo avg 1.2M
Live data · 2026-11-22 12:47 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed AARD - Filings & News (Page 2)

AARD
Mar 23, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $4.07
Real-time Price: $0.9226 info
Change: -$3.14 (-77%) info
Market Cap: $20.197M info
AARD
Feb 27, 2026, 4:27 PM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $6.50
Real-time Price: $0.9226 info
Change: -$5.58 (-86%) info
Market Cap: $20.197M info
AARD
Feb 27, 2026, 4:05 PM EST
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $12.49
Real-time Price: $0.9226 info
Change: -$11.57 (-93%) info
Market Cap: $20.197M info
AARD
Feb 12, 2026, 8:17 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $12.67
Real-time Price: $0.9226 info
Change: -$11.75 (-93%) info
Market Cap: $20.197M info
AARD
Feb 10, 2026, 8:14 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $13.06
Real-time Price: $0.9226 info
Change: -$12.14 (-93%) info
Market Cap: $20.197M info
AARD
Jan 12, 2026, 8:30 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $14.73
Real-time Price: $0.9226 info
Change: -$13.81 (-94%) info
Market Cap: $20.197M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets